Soru

Zorluk: OrtaMenstrual Cycle Abnormalities and Contraception

A 2626-year-old nulliparous woman comes to the clinic to discuss contraceptive options. She and her partner are sexually active and wish to avoid pregnancy for at least the next 33 years. Her menstrual periods occur every 2828 days, last for 77 to 88 days, and are associated with heavy bleeding that requires changing a super-absorbent pad every 22 hours on her heaviest days. Her past medical history is significant for episodic headaches that occur approximately once a month. These headaches are characteristically preceded by bilateral flashing lights and zig-zag lines, followed by throbbing unilateral head pain. She takes sumatriptan as needed with good relief. Her blood pressure is 118/76 mmHg118/76\text{ mmHg}, heart rate is 72/min72\text{/min}, and body mass index is 24 kg/m224\text{ kg/m}^2. A urine beta-hCG test is negative. Pelvic examination is unremarkable. Which of the following is the most appropriate contraceptive recommendation for this patient?

  1. A
    Copper-containing intrauterine device
  2. B
    Etonogestrel and ethinyl estradiol vaginal ring
  3. Levonorgestrel-releasing intrauterine deviceCevap
  4. D
    Oral ethinyl estradiol and levonorgestrel
  5. E
    Subdermal etonogestrel implant

Cevap

Levonorgestrel-releasing intrauterine device
The correct answer addresses both the patient's vascular risk profile and her gynecologic symptoms. Migraine with aura is an absolute contraindication (World Health Organization Medical Eligibility Criteria category 4) to any estrogen-containing contraceptive due to an unacceptably high risk of ischemic stroke. Therefore, combined oral contraceptives and vaginal rings must be strictly avoided. Among the safe, non-estrogen alternatives (progestin-only methods and the copper IUD), the levonorgestrel-releasing intrauterine device is the most appropriate. It provides highly effective contraception while powerfully thinning the endometrium, which directly treats her heavy menstrual bleeding.

Adım Adım Çözüm

1
Identify the patient's primary contraceptive needs and baseline medical conditions.
The patient needs highly effective contraception and suffers from two key conditions: heavy menstrual bleeding and migraines with visual aura.
Tailoring contraceptive choice requires balancing efficacy, non-contraceptive benefits (reducing bleeding), and absolute contraindications.
2
Apply the WHO Medical Eligibility Criteria (MEC) to eliminate contraindicated methods.
Estrogen-containing methods (combined oral pills, patches, vaginal rings) are eliminated.
Migraine with aura is a WHO MEC Category 4 (absolute contraindication) for estrogen use due to a significantly increased risk of ischemic stroke.
3
Evaluate the remaining safe methods (progestin-only options and copper IUD) for their impact on heavy menstrual bleeding.
The levonorgestrel-releasing IUD is selected as the optimal choice.
The copper IUD exacerbates heavy bleeding, and the subdermal implant causes irregular bleeding. The levonorgestrel IUD directly treats heavy menstrual bleeding by thinning the endometrium.

Anahtar Kavram

WHO Medical Eligibility Criteria for Contraceptive Use (Estrogen contraindication in Migraine with Aura) and management of Heavy Menstrual Bleeding.
Tahmini Süre:1m 15s
Bu soruyu puanla